U.S. Marine and Shipping Stock News

NYSE:IP
NYSE:IPPackaging

A Look At International Paper (IP) Valuation As It Reshapes Portfolio And Splits Into Two Companies

International Paper (IP) is in the middle of a major reshaping, closing its Georgetown container plant and preparing to split into separate North America and EMEA companies, while reallocating capital toward newer packaging assets. See our latest analysis for International Paper. Those portfolio moves sit against a share price of US$42.89, with a 90 day share price return of 13.32% and a 1 year total shareholder return decline of 19.17%. This suggests momentum has picked up recently even as...
NYSE:FIGS
NYSE:FIGSLuxury

Why FIGS (FIGS) Is Up 56.9% After Strong Q4 Beat And 2026 Growth Outlook

In late February 2026, FIGS, Inc. reported fourth-quarter 2025 revenue of US$201.9 million and net income of US$18.51 million, capping a full-year performance of US$631.1 million in sales and US$34.25 million in net income with sharply higher earnings per share versus 2024. Management paired these results with an outlook for 10% to 12% revenue growth in 2026, underscoring momentum from a larger active customer base, international expansion and improved operating margins. We’ll now examine...
NYSE:CWT
NYSE:CWTWater Utilities

How Investors Are Reacting To California Water Service Group (CWT) Weaker Earnings And Aggressive Expansion Push

In late February 2026, California Water Service Group reported that fourth-quarter 2025 sales eased to US$219.98 million and net income fell to US$11.48 million, with full-year 2025 sales of US$1,000.14 million and net income of US$128.21 million, reflecting lower water consumption and higher costs. At the same time, the company accelerated its expansion by agreeing to acquire Nexus Water Group’s Nevada and Oregon systems and the remaining interest in its Texas joint venture, while...
NasdaqGS:AARD
NasdaqGS:AARDPharmaceuticals

Aardvark Therapeutics (AARD) Is Down 56.5% After Pausing Phase 3 HERO Trial for ARD-101

Aardvark Therapeutics recently voluntarily paused its Phase 3 HERO trial of ARD-101 for hyperphagia in Prader-Willi Syndrome, and no longer expects to report topline data in the third quarter of 2026, with updated guidance now planned for the second quarter of 2026. The pause affects Aardvark’s lead asset in a rare disease setting where ARD-101 already holds both Orphan Drug and Rare Pediatric Disease designations from the FDA. We will now examine how the pause of the HERO Phase 3 trial for...
NYSE:NEM
NYSE:NEMMetals and Mining

Assessing Newmont (NEM) Valuation After Analyst Upgrades And Record Free Cash Flow Results

Newmont (NEM) is back in focus after a cluster of upbeat analyst calls linked to stronger gold sentiment, the agenda of its new CEO, and recent results featuring record free cash flow and near zero net debt. See our latest analysis for Newmont. Recent news around stronger free cash flow, buybacks and a higher fourth quarter dividend has arrived alongside a 42.27% 3 month share price return and a very large 1 year total shareholder return. This suggests momentum has been building rather than...
NYSE:HE
NYSE:HEElectric Utilities

What Hawaiian Electric Industries (HE)'s Wildfire-Era Profit Recovery Means For Shareholders

Hawaiian Electric Industries reported full-year 2025 revenue of US$3.09 billion, down slightly from US$3.22 billion in 2024, while swinging from a very large net loss to net income of US$123.12 million, or US$0.71 in basic and diluted earnings per share from continuing operations. The earnings rebound coincided with progress on Maui wildfire-related settlements, funded by insurance, and regulatory approval of a multi-year wildfire safety plan that supports both risk reduction and grid...
NYSE:NPO
NYSE:NPOMachinery

Is It Too Late To Consider Enpro (NPO) After Its Strong Multi Year Share Price Run?

If you are wondering whether Enpro's current share price really reflects its underlying worth, this article walks through what the numbers actually say about value. Enpro's share price recently closed at US$264.05, with returns of 10.6% over 30 days, 20.5% year to date, 49.2% over 1 year, 155.4% over 3 years and 205.4% over 5 years. These figures may catch the eye of investors thinking about future risk and reward. Recent coverage around Enpro has focused on its role within the capital goods...
NasdaqCM:PLUG
NasdaqCM:PLUGElectrical

Plug Power (PLUG) Valuation Check As Positive Gross Margin And 30% Revenue Growth Reset Expectations

Plug Power (PLUG) is back in focus after its latest earnings showed gross margin turning positive alongside about 30% annual revenue growth, while a new CEO and capital decisions framed its ongoing push to reduce sizeable losses. See our latest analysis for Plug Power. Despite a recent 1 month share price decline of 14% and year-to-date share price weakness, Plug Power’s 1 year total shareholder return of 20.67% shows longer term investors have seen a very different experience. Recent...
NYSE:AES
NYSE:AESRenewable Energy

AES (AES) Valuation Check After Choppy Returns And Conflicting Fair Value Signals

Why AES (AES) is on investors’ radar today AES (AES) is drawing attention after a mixed run in its share price, with a 1 day return of around 0.18% and a past 3 months total return of about 1.79%. Over the past year, the stock’s total return of roughly 34.25% contrasts with weaker multi year figures. At the same time, annual revenue of about US$12.1b and net income of roughly US$1.1b frame the current debate around valuation and business momentum. See our latest analysis for AES. That sharp 1...
NYSE:RYN
NYSE:RYNSpecialized REITs

Rayonier (RYN) Valuation Check After Dividend Adjustment And Lower Short Interest

Why Rayonier’s latest dividend move is drawing fresh attention Rayonier (RYN) has drawn fresh attention after its board set the first quarter cash dividend at $0.26 per share, a trim from $0.2725, following a December special dividend and recent shifts in short interest. See our latest analysis for Rayonier. For context, Rayonier’s share price now sits at US$21.64, with a 1 day share price return of 0.70% and a 90 day share price return of 0.98%. The 1 year total shareholder return of 11.76%...
NasdaqGS:EZPW
NasdaqGS:EZPWConsumer Finance

A Look At EZCORP (EZPW) Valuation After Consistent Earnings Beats And Analyst Strong Buy Ratings

Recent enthusiasm around EZCORP (EZPW) has been driven by consistent earnings outperformance, with four straight quarters above expectations and analysts highlighting the shares as undervalued relative to industry peers on several valuation metrics. See our latest analysis for EZCORP. That upbeat valuation story is playing out in the price action, with EZCORP’s share price at US$27.17 after a 30 day share price return of 26.67% and a year to date share price return of 35.44%, set against a...
NasdaqGS:GFS
NasdaqGS:GFSSemiconductor

Is Shifting Short Interest Reframing GlobalFoundries’ (GFS) Risk Reward Profile in Semiconductor Foundries?

Recently, GLOBALFOUNDRIES Inc. reported that short interest as a share of its freely tradable float fell 6.2%, to 12.7%, still well above the 4.53% average for peers. This decline suggests a shift in sentiment even as the company remains one of the more heavily shorted names among comparable semiconductor foundries. We’ll now explore how this reduction in short interest fits into GlobalFoundries’ broader investment narrative and evolving risk-reward profile. The future of work is here...
NYSE:PEG
NYSE:PEGIntegrated Utilities

A Look At Public Service Enterprise Group (PEG) Valuation As Short Term Momentum Softens

Public Service Enterprise Group (PEG) has drawn fresh attention as investors reassess its recent share performance, with the stock showing mixed short term moves but positive returns over the past month and past 3 months. See our latest analysis for Public Service Enterprise Group. The recent pullback, including a 1 day share price return of 1.82% decline to US$84.50 and a softer 7 day share price return of 2.10% decline, comes after steadier gains. The 30 day and 90 day share price returns...
NasdaqGS:ZS
NasdaqGS:ZSSoftware

How Investors Are Reacting To Zscaler (ZS) Raising 2026 Guidance Despite a Wider Quarterly Loss

In late February 2026, Zscaler reported second-quarter results showing revenue rising to US$815.75 million while its net loss widened to US$34.31 million, and the company raised both third-quarter and full-year fiscal 2026 revenue and annual recurring revenue guidance. At the same time, Zscaler’s higher spending in a competitive market and concerns around billings, new customer growth, and integration of acquired businesses have led investors to question how durable its growth and path...
NasdaqCM:UFPT
NasdaqCM:UFPTMedical Equipment

UFP Technologies Deepens Intuitive Surgical Ties With Expanded Long Term Deal

UFP Technologies (NasdaqCM:UFPT) amended its manufacturing supply agreement with Intuitive Surgical. The amendment extends the term of the partnership between the two companies. Minimum volume commitments under the agreement were increased. A new program for additional products was added to the supply arrangement. For you as an investor, this centers on UFP Technologies' role as a specialized manufacturer for the medical device sector, supplying components and solutions to a leading global...
NYSE:MOD
NYSE:MODBuilding

Is Modine Manufacturing (MOD) Fairly Priced After Its Sharp Multi‑Year Share Price Surge

If you are wondering whether Modine Manufacturing's current share price actually lines up with its underlying worth, you are not alone. This article is going to focus squarely on what the numbers say about value. The stock last closed at US$238.50, with returns of 7.2% over 7 days, 29.2% over 30 days, 69.4% year to date and 209.2% over 1 year, while the 3 year return is very large and the 5 year return is around 15x. Recent news around Modine Manufacturing has largely centered on its role in...
NYSE:XPRO
NYSE:XPROEnergy Services

A Look At Expro Group Holdings (XPRO) Valuation After Earnings Guidance And New Buyback Program

Earnings, guidance and new buyback put Expro Group Holdings (XPRO) in focus Expro Group Holdings (XPRO) is back on investors’ radar after releasing fourth quarter and full year 2025 results, setting 2026 revenue guidance, and unveiling a new US$100 million share repurchase plan. The latest numbers give you a fresh look at how the business ended 2025. The guidance and buyback outline how management is thinking about the next phase. Here is what stands out from the announcement and how you...
NasdaqGM:HROW
NasdaqGM:HROWPharmaceuticals

Harrow’s PharmaPack Aims To Reshape Post Cataract Care And Cash Pay Use

Harrow (NasdaqGM:HROW) has introduced a new Direct-to-Prescriber PharmaPack offering focused on post-cataract surgery care. The PharmaPack kits provide access to FDA-approved ophthalmic products and are designed to be ordered directly by eye care providers. The launch aims to reduce reliance on off-label compounded formulations and support more standardized treatment protocols. For investors following ophthalmic therapeutics, Harrow sits at the intersection of branded eye care drugs and...
NYSE:OWL
NYSE:OWLCapital Markets

Blue Owl’s Liquidity Crackdown and ESOP Shelf Might Change The Case For Investing In OWL

In February 2026, Blue Owl Capital Inc. filed a US$615.5 million shelf registration for 50,000,000 Class A shares linked to an employee stock ownership plan, shortly after restricting withdrawals from a fund and planning to sell US$1.40 billion of assets across three funds to repay debt and return capital to investors. These moves, including the permanent removal of a quarterly withdrawal option in its smallest vehicle, highlight how Blue Owl is balancing growth ambitions with tighter...
NasdaqGS:SVRA
NasdaqGS:SVRABiotechs

Why Savara (SVRA) Is Up 5.4% After FDA Grants Priority Review To MOLBREEVI Application

Savara Inc. recently announced that the FDA has accepted for review its Biologics License Application for MOLBREEVI to treat autoimmune pulmonary alveolar proteinosis (autoimmune PAP) and granted the therapy Priority Review, with a PDUFA action date set for August 22, 2026. The drug’s combination of Priority Review, Fast Track, Breakthrough Therapy, Orphan Drug, Innovation Passport, and Promising Innovative Medicine designations highlights both its potential clinical importance and the high...
NYSE:TFC
NYSE:TFCBanks

Is Truist Financial (TFC) Pricing Reflect Its Recent Returns And Valuation Metrics

If you are wondering whether Truist Financial's current share price really lines up with its underlying worth, this article will walk through the key numbers that matter most. Over the short term, the stock has seen a 1.1% decline over 7 days and a 3.6% decline over 30 days. The longer term picture shows a 14.3% return over 1 year, 26.4% over 3 years, and 5.1% over 5 years from a last close of US$49.55. Recent market attention around large US banks has kept Truist Financial in focus,...
NYSE:XPEV
NYSE:XPEVAuto

Is XPeng (XPEV) Pricing In Too Much Hope After Prolonged Share Price Weakness

If you are wondering whether XPeng shares are pricing in too much hope or not enough, this article walks through what the current valuation really implies for investors. The stock recently closed at US$16.99, with returns of a 3.2% decline over 7 days, a 5.5% decline over 30 days, a 16.8% decline year to date, a 16.1% decline over 1 year and an 81.3% decline over 3 years, which gives a mixed picture of sentiment and risk. Recent headlines around XPeng have focused on broad themes such as...
NYSE:SM
NYSE:SMOil and Gas

SM Energy Refocuses Portfolio Toward Debt Reduction And Shareholder Returns

SM Energy (NYSE:SM) completed a US$950 million South Texas asset sale, aimed at reshaping its portfolio and paying down debt. The company announced a 10% increase in its quarterly dividend alongside a new US$500 million share repurchase program. These capital moves follow the recently completed merger with Civitas, signaling a sharper focus on shareholder returns. SM Energy, an independent oil and gas producer, is refocusing its portfolio at a time when many energy companies are rethinking...
NasdaqCM:EXAS
NasdaqCM:EXASBiotechs

Exact Sciences Holders Back Abbott Deal As Valuation Gap Draws Focus

Shareholders of Exact Sciences (NasdaqCM:EXAS) have approved the proposed acquisition by Abbott Laboratories. The vote clears a key step in the transaction process and moves the deal closer to completion. The approval reflects investor backing for the planned combination of the two healthcare companies. Exact Sciences focuses on cancer screening and diagnostic tests, an area that attracts attention as healthcare systems look for earlier detection and more personalized care. The approved...